Detail akcie UCB SA online

Business Summary: Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
Financial Summary: BRIEF: For the six months ended 30 June 2024, UCB SA revenues increased 8% to EUR2.79B. Net income decreased 33% to EUR208M. Revenues reflect Bimzelx segment increase from EUR52M to EUR215M, Briviact segment increase of 20% to EUR327M, USA segment increase of 17% to EUR1.38B, Germany segment increase of 11% to EUR165M. Net income was offset by Marketing and selling expenses increase of 25% to EUR945M (expense).